Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Dahan Michel
 2. Date of Event Requiring Statement (Month/Day/Year)
03/10/2016		 3. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [AKBA]
(Last)
(First)
(Middle)
C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, Chief Business Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CAMBRIDGE, MA 02142		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 27,261
D
 
Common Stock 20,500 (1)
D
 
Common Stock 28,596 (2)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (3) 02/22/2026 Common Stock 30,950 $ 7.7 D  
Stock Option (Right to Buy)   (4) 09/30/2025 Common Stock 15,000 $ 9.66 D  
Stock Option (Right to Buy)   (5) 03/06/2025 Common Stock 30,000 $ 11.15 D  
Stock Option (Right to Buy)   (6) 05/14/2024 Common Stock 6,667 $ 22.8 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Dahan Michel
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET, SUITE 1100
CAMBRIDGE, MA 02142		       SVP, Chief Business Officer  

Signatures

/s/ Nicole R. Hadas, attorney-in-fact for Michel Dahan 03/18/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The restricted stock units were granted by the Issuer on February 22, 2016 pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the Grant Date.
(2) These shares are restricted stock issued pursuant to the December 23, 2013 restricted stock agreement. The shares will vest as follows: 25% vested on December 2, 2014, and the remaining shares will vest in equal quarterly installments over the following three years through December 2, 2017.
(3) This option was granted February 22, 2016. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
(4) This option was granted September 30, 2015. 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
(5) This option was granted March 6, 2015. 25% of this option vested on the first anniversary of the grant date and the remaining 75% will vest in equal quarterly installments thereafter.
(6) This option was granted May 14, 2014. 25% of this option vested on the first anniversary of the grant date and the remaining 75% will vest in equal quarterly installments thereafter.
 
Remarks:
Exhibit List
Exhibit 24 - Limited Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.